Apremilast Medicine 05 December 2023 Extended indication Treatment of psoriatic arthritis, psoriasis, Behçet’s disease Therapeutic value No estimate possible yet Total cost Registration phase No registration expected Product Active substance Apremilast Domain Chronic immune diseases Reason of inclusion Generic G Main indication Unknown Extended indication Treatment of psoriatic arthritis, psoriasis, Behçet’s disease Current proprietary name Otezla Already available biosimilars / generics Proprietary name Manufacturer Portfolio holder Mechanism of action Enzyme inhibitor Route of administration Oral Therapeutical formulation Tablet Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date March 2023 Expected Registration April 2024 Orphan drug Unknown Registration phase No registration expected Reimbursement Medicine sluice Additional remarks Registratieaanvraag teruggetrokken oktober 2024 Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks